July 22, 2026 08:00 ET | Source: LB Pharmaceuticals Inc
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of LB-102 for the treatment of schizophrenia. The trial is designed to enroll approximately 460 patients across 25 sites in the U.S.
“Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected, which we believe is a reflection of both the strength of our execution and the level of interest in LB-102 as a potential new treatment for schizophrenia. Based on the pace of enrollment since initiating NOVA-2, we now expect to report topline results in the first half of 2027, ahead of our prior guidance of the second half of 2027, and to schedule a pre-NDA meeting soon thereafter in the second half of 2027,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We remain well capitalized with a cash runway expected to fund operations into the second quarter of 2029 through multiple clinical readouts, with topline data from the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression expected in the first quarter of 2028, and from the Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029.”
About LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT-7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.
About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of LB-102, including the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open label trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression and the Phase 2 trial for the adjunctive treatment of MDD; and anticipated cash runway into the second quarter of 2029. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
July 14, 2026 06:30 ET | Source: Haoxi Health Technology Limited
BEIJING, July 14, 2026 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), a Beijing-headquartered online marketing solutions provider specializing in one-stop digital marketing services for the health and wellness industry, today announced the signing of a strategic cooperation framework agreement with NOVA MEDIA, a technology company with expertise in AI digital humans and generative AI.
Under the agreement, NOVA MEDIA will develop an AI digital marketing system (the “System") for HAO that is designed to support content production through AI-enabled tools and standardized workflows.
The System will integrate AI digital human technology, automated content generation, and end-to-end workflow automation to support HAO's health-industry marketing operations. By leveraging NOVA MEDIA’s generative AI capabilities alongside HAO's industry knowledge, the collaboration aims to deliver advanced AI marketing solutions.
The strategic cooperation framework will focuses on developing automating creative content generation and enhancing intelligent decision-making processes to deliver digital marketing solutions to HAO's vast client base across popular Chinese platforms, including Toutiao, Douyin, WeChat, and Sina Weibo .
The collaboration aims to support HAO's expansion into AI-enabled marketing solutions and builds on the Company's track record of helping healthcare advertisers reduce costs, increase efficiency, and acquire customers through innovative online marketing strategies.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider specializing in serving healthcare industry advertiser clients. The Company offers one-stop online marketing solutions, particularly in online short video marketing, helping advertisers acquire and retain customers on popular Chinese platforms. For more information, visit: http://ir.haoximedia.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2026) - EraNova Metals Inc. (TSXV: NOVA) (OTCQB: STXPF) ("EraNova" or the "Company") is pleased to provide an update on its 2026 summer exploration program, which is now underway at its 100%-owned, 29,700-hectare Ruby Creek Property near Atlin, British Columbia.
"Our objective this season is straightforward — continue building a pipeline of high-quality drill targets across Ruby Creek," said Meredith Eades, President and CEO of EraNova. "While the Adanac Molybdenum Project advances toward a NI 43-101 compliant Preliminary Economic Assessment, our exploration team continues to demonstrate the broader district-scale potential of the property. Every field season adds to our understanding of this large, highly prospective mineral system."
2026 Exploration Program
Geological mapping and prospecting across priority target areasSoil geochemical surveys to expand and refine known mineralized trendsGround geophysical surveys to better define subsurface targetsContinued evaluation and prioritization of multiple exploration targets across the propertyGeneration of new drill targets for future exploration programs
Figure 1. Overview of the 2026 exploration program at the Ruby Creek Property highlighting the Company's priority exploration targets and planned field activities.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11821/304373_72b6f415d42939ea_001full.jpg
Figure 2. Ground geophysical surveys underway at the Ruby Creek Property as part of EraNova's 2026 exploration program to refine priority exploration targets and support future drill testing.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11821/304373_eranovaimg2.jpg
The 2026 program is designed to advance and refine high-priority exploration targets across the property through a combination of geological mapping, prospecting, soil geochemistry and geophysical surveys. The work will focus on further defining existing mineralized trends and identifying new drill targets for future exploration programs.
The exploration program builds upon the Company's recent discoveries at the Lakeview Gold-Silver System, Ruffner Copper-Gold Porphyry, and Silver Surprise Zone, while continuing to evaluate numerous additional target areas identified across the Ruby Creek district.
The 2026 exploration program complements the advancement of the Adanac Molybdenum Project toward a NI 43-101 compliant Preliminary Economic Assessment ("PEA"). Together, these initiatives reflect EraNova's strategy of advancing both development-stage and exploration-stage opportunities across the Ruby Creek district.
Further updates will be provided as results from the 2026 exploration program become available.
Qualified Person
Mr. Nicholas Clive Aspinall, M.Sc., P.Eng., is a consulting geologist to EraNova Metals and is a "Qualified Person" as defined by National Instrument 43-101. Mr. Aspinall has reviewed and approved the scientific and technical information contained in this news release.
About EraNova Metals Inc.
EraNova Metals is a Canadian mineral exploration company focused on advancing precious and base metal projects across western Canada.
The Company's flagship asset is the Ruby Creek Property, a 29,700-hectare land package near Atlin, BC that hosts both the Adanac Molybdenum Project, a development-stage deposit with historic feasibility, and the Atlin Discovery Project, an emerging pipeline of high-grade gold, silver, copper, and tungsten zones.
EraNova also holds two additional 100%-owned assets: the Big Ledge Zinc-Lead Project, located 57 km south of Revelstoke, BC, and the South Thompson Nickel Project in west-central Manitoba.
For further information on EraNova, visit our website at www.eranovametals.com or contact:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's 2026 exploration program, the scope and timing of exploration activities, the generation and advancement of exploration targets, the identification of future drill targets, the completion and timing of the Preliminary Economic Assessment on the Adanac Molybdenum Project, and the Company's plans, objectives and future exploration and development activities.
Forward-looking statements are based on a number of assumptions believed by management to be reasonable at the time such statements are made, including assumptions regarding the availability of financing, the completion of planned exploration activities, the receipt of required permits and regulatory approvals, favourable weather and field conditions, the availability of personnel and contractors, and general business and economic conditions. Actual results may differ materially from those expressed or implied by such forward-looking statements due to risks and uncertainties including, but not limited to, changes in market conditions, commodity prices, permitting delays, operational risks, weather conditions, financing availability, exploration results, and other risks inherent in the mineral exploration industry.
Readers are cautioned not to place undue reliance on forward-looking statements. EraNova undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304373
Source: EraNova Metals Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2026) - EraNova Metals (TSXV: NOVA) (OTCQB: STXPF) is advancing a large molybdenum resource in British Columbia supported by previous engineering studies, over $100 million in infrastructure investment, and a 433-million-pound molybdenum resource. The same property hosts a polymetallic corridor that has not yet been drill-tested but has returned high-grade gold and silver grab sample results. The company's dual-track strategy provides exposure to a development-stage critical mineral asset alongside early-stage exploration upside on one property.
For over 25 years, BTV has been a capital markets focused TV production and Digital Marketing Agency. BTV helps companies increase their brand awareness to a national retail and institutional investor audience, combining unique content creation and major distribution services on top tier networks including Bloomberg, CNBC, FOX Business News and financial sites. The BTV suite of strategic products include: BTV- Business Television Show, CEO Clips™, TV Branding Ads, Digital, Lead Gen, Social and Direct Email Marketing Campaigns that reach investors where they research and live on-air and online.
Discover Investment Opportunities!
www.b-tv.com/theagency
About CEO Clips:
CEO Clips - are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the initiation of its pivotal Phase 3 trial (NOVA-2) evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia March 27, 2026 12:00 ET | Source: LB Pharmaceuticals Inc
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. The post hoc analysis was designed to assess whether the improvement in cognitive performance, as measured by the Global Cognition composite score, was a direct effect of LB-102 or an indirect consequence of the effect of LB-102 on total schizophrenia symptoms. Results of the analysis demonstrated that the cognitive benefit was primarily, and statistically significantly, a direct effect of LB‑102. The presentation, titled “LB-102 for Cognition in Patients with Schizophrenia: An Exploratory Post Hoc Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2 Study” was highlighted at the Schizophrenia International Research Society (SIRS) meeting on March 27th in Florence, Italy.
“There remains significant unmet need for new schizophrenia therapies that offer patients the potential for improvements in cognitive symptoms that drive functional impairment,” said Anna Eramo, M.D., Chief Medical Officer of LB Pharmaceuticals. “This new analysis provides additional insights into the potential of LB-102 to offer differentiated improvement in cognitive performance that is independent of its effect on overall schizophrenia symptoms. Based on these robust data, we are prospectively evaluating cognitive performance as a secondary endpoint in our recently initiated pivotal Phase 3 trial (NOVA-2) of LB-102 in patients with acute schizophrenia, our planned open label extension trial in patients with schizophrenia, as well as our ongoing and planned trials in bipolar 1 depression and adjunctive MDD.”
In addition, an encore oral presentation titled "LB-102 for Acute Schizophrenia in Adults: Results from the Phase 2 NOVA-1 Clinical Trial, with a Focus on PANSS Marder Factor Scores” was also presented at SIRS. This presentation reviewed an analysis exploring LB-102’s effect on PANSS Marder factor, which provides a more nuanced framework for understanding the complexities of schizophrenia symptoms. This analysis evaluated LB‑102’s effects across the five PANSS Marder factors: Positive Symptoms, Negative Symptoms, Disorganized Thought, Hostility/Excitability, and Anxiety/Depression.
In the Phase 2 NOVA-1 trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial. LB-102 was generally safe and well tolerated, exhibiting a potentially class-leading safety profile with low rates of extrapyramidal symptoms (EPS) (including akathisia), minimal sedation and few gastrointestinal (GI) side effects alongside effects on negative symptoms and cognitive performance. A dose dependent, and statistically significant improvement in the global cognition composite score was observed at all dose levels in a patient population that was not enriched for severe cognitive impairment at baseline.
In addition to the oral and poster presentation, the Company sponsored a Satellite Symposium titled “Next-Generation Perspectives in Schizophrenia: Translating Emerging Science Into Practice” featuring John Kane, M.D., Professor, Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine and Christoph Correll, M.D., Professor of Child and Adolescent Psychiatry at the Charité-Universitätsmedizin Berlin and Donald and Barbara Zucker School of Medicine.
The poster and oral presentations are available on the LB Pharma Publication page on LB Pharmaceuticals website at https://lbpharma.us/.
About LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the U.S., LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT-7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. A Phase 3 clinical trial (NOVA-2) of LB-102 for schizophrenia and a Phase 2 clinical trial (ILLUMINATE-1) of LB-102 for bipolar depression have been initiated, and a Phase 2 trial in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the therapeutic benefits of LB-102; and the design, objectives, initiation, timing, progress and results of current and future clinical trials of LB-102, including the Phase 2 NOVA-1 trial and the Phase 3 NOVA-2 trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - EraNova Metals Inc. (TSXV: NOVA) (OTCQB: STXPF) ("EraNova" or the "Company") announces its participation at the John Tumazos Very Independent Research 2026 Virtual Conference. Meredith Eades, President and CEO and Janet Miller, Geologist will participate virtually on Wednesday, April 1, 2026, from 12:15 p.m.
Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Meredith Eades, President and Chief Executive Officer, EraNova Metals Inc. ("EraNova Metals" or the "Company") (TSXV: NOVA), shares the Company's story in an interview with TMX Group. Cannot view this video?
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizophrenia: A Phase 2 Randomized Clinical Trial.” LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - EraNova Metals Inc. (TSXV: NOVA) (OTCQB: STXPF) (the "Company" or "EraNova") is pleased to announce a non-brokered private placement (the "Private Placement") of up to 4,000,000 common shares of the Company ("Common Shares") at a price of $0.15 per Common Share for gross proceeds of up to $600,000.
The Company intends to use the net proceeds from the Private Placement to support ongoing technical work and completion of the NI 43-101 compliant Preliminary Economic Assessment ("PEA") on the Adanac Molybdenum Project, alongside marketing and investor awareness initiatives, and for general working capital purposes.
"Closing this financing is a significant step forward that allows us to finalize the completion of our Preliminary Economic Assessment, moving EraNova one step closer to proving the economic foundation of our flagship Adanac Molybdenum Project," stated Meredith Eades, President and CEO. "With our treasury bolstered, we are now fully funded to deliver this critical value-driving milestone, unlocking further potential for our shareholders into 2026."
The Ruby Creek Property hosts the Adanac Molybdenum Project alongside a growing pipeline of high-grade copper, gold, silver, tungsten, and rare earth element targets across the broader district-scale property.
It is anticipated that certain directors, officers or other insiders of the Company may acquire Common Shares under the Private Placement. Such participation will be considered a "related party transaction" within the meaning of TSX Venture Exchange Policy 5.9 (the "Policy") and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") adopted in the Policy. The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Private Placement, as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves related parties, is expected to exceed 25% of the Company's market capitalization (as determined under MI 61-101).
Closing of the Private Placement is expected to occur as soon as practicable and may take place in one or more tranches. In connection with the Private Placement, the Company may pay finder's fees in cash of up to 7% of the gross proceeds from the sale of the Common Shares placed by the finders in accordance with the policies of the TSX Venture Exchange.
The Private Placement is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. All securities issued under the Private Placement will be subject to a four-month and one-day statutory hold period in accordance with applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any applicable U.S. state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
About EraNova Metals Inc.
EraNova Metals is a Canadian mineral exploration and development company focused on advancing a portfolio of precious and base metal assets across western Canada.
The Company's flagship asset is the 29,700-hectare Ruby Creek Property near Atlin, British Columbia, which hosts the Adanac Molybdenum Project - a development-stage deposit currently advancing toward a NI 43-101 compliant Preliminary Economic Assessment ("PEA") - alongside a growing pipeline of high-grade copper, gold, silver, tungsten, and rare earth element targets across the broader district-scale property.
EraNova also holds a 100% interest in both the Big Ledge Zinc Project, located south of Revelstoke, British Columbia, and the South Thompson Nickel Project in Manitoba.
For further information on EraNova Metals, visit our website at eranovametals.com or contact:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This news release contains certain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements"). Forward-looking statements in this release include, but are not limited to, statements regarding: the completion and timing of the Private Placement; the anticipated use of proceeds; the advancement of the Ruby Creek Project and the Adanac Molybdenum Project; the completion and timing of a NI 43-101 compliant Preliminary Economic Assessment; the advancement of exploration targets across the broader property; insider participation in the Private Placement; the payment of finder's fees; the receipt of regulatory approvals, including approval of the TSX Venture Exchange; and the closing of the Private Placement in one or more tranches.
Forward-looking statements are based on a number of assumptions believed by management to be reasonable at the time such statements are made, including, without limitation: the Company's ability to complete the Private Placement on the terms described herein; the receipt of all necessary regulatory approvals in a timely manner; the use of proceeds of the Private Placement as currently anticipated; the availability of financing, labour, equipment and supplies; the timely advancement of technical studies and exploration activities; the accuracy of geological interpretations; and general business and economic conditions.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the risk that the Private Placement may not be completed as anticipated or at all; delays in obtaining regulatory approvals; changes in market conditions or commodity prices; risks related to exploration, development and operations; the risk that costs may exceed budget; risks related to permitting and environmental regulation; uncertainty in geological interpretations; financing risks; and other risks disclosed in the Company's public disclosure documents available under the Company's profile on SEDAR+.
Forward-looking statements are based on the expectations and opinions of the Company's management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. The forward-looking statements contained in this news release are made as of the date of this release, and the Company does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297875
Source: EraNova Metals Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2026) - EraNova Metals Inc. (TSXV: NOVA) (OTCQB: STXPF) ("EraNova" or the "Company") is pleased to announce that it will be participating in two upcoming investor conferences as the Company advances the Adanac Molybdenum Project toward a NI 43-101 compliant Preliminary Economic Assessment ("PEA") and continues to increase awareness of the broader Ruby Creek district. EraNova is also pleased to announce that it has engaged Investing News Network, NorthStar Communications Canada Corp., and Milky Way Marketing Inc. and Blue Sun Productions Inc. to provide investor relations services.
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - EraNova Metals Inc. (TSXV: NOVA) (OTCQB: STXPF) (the "Company" or "EraNova") is pleased to announce the closing of its previously announced non-brokered private placement (the "Private Placement"), raising gross proceeds of $627,524.70 through the issuance of 4,183,498 common shares of the Company (the "Common Shares") at a price of $0.15 per Common Share. The Company announced the Private Placement on May 19, 2026, for gross proceeds of up to $600,000.
